Targeting tumor suppressor genes for cancer therapy
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Cancer drugs are broadly classified into two categories: cytotoxic chemotherapies and targeted therapies that specifically modulate the activity of one or more proteins involved in cancer. Major advances have been achieved in targeted cancer therapies in the past few decades, which is ascribed to the increasing understanding of molecular mechanisms for cancer initiation and progression. Consequently, monoclonal antibodies and small molecules have been developed to interfere with a specific molecular oncogenic target. Targeting gain‐of‐function mutations, in general, has been productive. However, it has been a major challenge to use standard pharmacologic approaches to target loss‐of‐function mutations of tumor suppressor genes. Novel approaches, including synthetic lethality and collateral vulnerability screens, are now being developed to target gene defects in p53, PTEN, and BRCA1/2. Here, we review and summarize the recent findings in cancer genomics, drug development, and molecular cancer biology, which show promise in targeting tumor suppressors in cancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“shown that Nutlin resembles an Mdm2binding peptide that competitively interacts with MDM2, leading to p53 stabilization and activation [87, 88].”
BackgroundThe DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368 · cited 3×
“In other words, what are driver genomic events? A primary feature of cancers is genetic instability arising from defects in DNA damage signaling and repair pathways [11].”
BackgroundInfluentialComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680 · cited 1×
“and ovarian cancer is inheritance of a mutation in one of the breast cancer susceptibilitygenes,BRCA1orBRCA2[107, 108].”
BackgroundChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
A census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184 · cited 1×
“The Cancer Gene Census is a manually curated set of genes that have potentially causative mutations or other genomic abnormalities in human cancers [38].”
BackgroundBlinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 2×
“Mostgenotoxicand chemotherapeutic drugs, such as alkylating agents and platinum-based drugs, trigger DNA damage response, and thus activate thep53pathway, but those effects are non-specific and also cause systemic toxicity [83].”
BackgroundGreaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
Raise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979
Cited by
Regulating tumor suppressor genes: post-translational modifications
Chen, L., Liu, S., & Tao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0196-9 · Cited by 449
“Previous studies indicate that only a copy of a TSG is enough to manipulate cell proliferation; in this way, two alleles of a TSG must be consistently inactivated or deleted to bring about tumorigenesis.(17,18) Therefore, the earliest identification methods relied on genetic methods, biallelic gene inactivation for ex…”
BackgroundMethodTargeting ARID1A mutations in cancer
Mullen, J., Kato, S., Sicklick, J. K., & Kurzrock, R. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102287 · Cited by 186
Postwala, H., Shah, Y., Parekh, P. S., & Chorawala, M. R. (2023) · Medical Oncology · doi:10.1007/s12032-023-02201-8 · Cited by 26
Metadata
- Authors
- Liu, Y., Hu, X., Han, C., Wang, L., Zhang, X., He, X., & Lu, X.
- Venue
- BioEssays
- Publisher
- Wiley
- Published
- 2015-10-07
- Volume
- 37
- Issue
- 12
- Pages
- 1277-1286
- ISSN
- 0265-9247 (ISSN-L)
- 1521-1878
- OpenAlex
- W1926951007
- Cited by
- 107
- References
- 31
- FWCI
- 0.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting tumor suppressor genes for cancer therapy. https://app.cochat.ai/papers/10.1002/bies.201500093
- The paper
- Liu, Y., Hu, X., Han, C., Wang, L., Zhang, X., He, X., & Lu, X. (2015). Targeting tumor suppressor genes for cancer therapy. BioEssays. https://doi.org/10.1002/bies.201500093
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.